Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells.
Previous studies have suggested that soy isoflavones exert anticarcinogenic effects against prostate cancer. We propose that soy extracts, containing a mixture of soy isoflavones and other bioactive components, would be a more potent chemo-preventive agent than individual soy isoflavones. We compared the apoptotic effects of whole soy extracts and individual soy isoflavones, genistein and daidzein, on prostate cancer cells. The soy extract contained 50% w/w of total isoflavones with approximately 1:5.5:3.5 ratios of genistin, daidzin and glycitin, respectively. Benign prostate hyperplasia (BPH-1), LnCap and PC3 cells were treated with varying concentrations of soy extract, genistein or daidzein and analyzed for cell cycle alterations and induction of apoptosis. At equal concentrations (25 micromol/L), soy extract induced a significantly higher percentage of cells undergoing apoptosis than genistein or daidzein (P < 0.001). No significant changes in cell cycle arrest or apoptosis were observed in non-cancerous BPH-1 cells treated with soy extract, suggesting that the effects of soy extract may be tumor cell specific. On the contrary, both genistein and daidzein induced apoptosis in BPH-1 cells, suggesting that individual isoflavones may have cytotoxicity in non-cancerous cells. Soy extracts also increased Bax expression in PC3 cells, but no significant changes in nuclear factor kappaB (NF kappaB) activation were detected, suggesting that the induction of apoptosis was independent of the NF kappaB pathway. Food products that bear a combination of active compounds may be more efficacious and safer as chemo-preventive agents than individual compounds. This 'whole-food'-based approach is significant for the development of public health recommendations for prostate cancer prevention.
Hsu
Anna
A
Department of Nutrition and Exercise Sciences, 103 Milam Hall, Oregon State University, Corvallis OR 97331, USA.
Bray
Tammy M
TM
Helferich
William G
WG
Doerge
Daniel R
DR
Ho
Emily
E
D016588:Anticarcinogenic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D019587:Dietary Supplements; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D048789:Phytoestrogens / Q000494:pharmacology; D010936:Plant Extracts / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013025:Glycine max / Q000737:chemistry*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D016588:Anticarcinogenic Agents; C494826:BAX protein, human; D007529:Isoflavones; D016328:NF-kappa B; D048789:Phytoestrogens; D010936:Plant Extracts; D051028:bcl-2-Associated X Protein; C040641:genistin; C004742:daidzein; D020169:Caspases
Mutagenesis. 1994 Mar;9(2):101-6
8201941
Carcinogenesis. 1996 Jul;17(7):1451-7
8706248
Nutr Cancer. 2007;57(2):184-93
17571952
Anal Biochem. 1976 May 7;72:248-54
942051
Jpn J Cancer Res. 2000 Feb;91(2):164-73
10761703
Cancer Res. 1993 Mar 15;53(6):1328-31
8443813
Prostate. 2002 May 1;51(2):133-40
11948968
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Prostate Cancer Prostatic Dis. 2008;11(1):6-12
17923857
BJU Int. 2005 Dec;96 Suppl 2:30-4
16359436
Cancer Res. 1998 Dec 1;58(23):5315-20
9850056
Nutr Cancer. 1999;35(2):167-74
10693171
J Nutr. 2005 Jun;135(6):1400-6
15930444
Urology. 2004 Sep;64(3):510-5
15351581
Int J Cancer. 2005 Nov 20;117(4):667-9
15945102
Oncol Rep. 2008 Apr;19(4):1061-6
18357397
J Agric Food Chem. 2005 Nov 2;53(22):8542-50
16248551
Nutr Cancer. 1999;33(2):125-31
10368806
J Nutr. 2002 Oct;132(10):3168-71
12368413
Am J Clin Nutr. 2000 Jun;71(6 Suppl):1705S-7S; discussion 1708S-9S
10837323
Int J Oncol. 2004 Nov;25(5):1389-95
15492830
J Urol. 1999 Jan;161(1):152-5
10037388
Prostate. 2006 Apr 1;66(5):557-66
16372328
J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S
15570058
Biochim Biophys Acta. 2007 Jun;1773(6):903-11
17490757
Annu Rev Plant Biol. 2004;55:225-61
15377220
Cancer Invest. 2003;21(5):744-57
14628433
J Nutr. 2007 Apr;137(4):964-72
17374662
Oncogene. 2008 Oct 20;27(48):6252-75
18931692
J Biol Chem. 1987 Apr 25;262(12):5592-5
3106339
Br J Nutr. 2004 Apr;91(4):513-31
15035679
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45
17337648
J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53
8382517
Proc Soc Exp Biol Med. 1998 Mar;217(3):310-6
9492340
J Nutr. 2001 Nov;131(11 Suppl):3095S-108S
11694655
Oncogene. 2003 Jul 24;22(30):4702-9
12879015
Toxicol Lett. 2004 Apr 15;150(1):43-56
15068824
Prostate. 2001 May 15;47(3):183-8
11351347
Lancet. 1993 Nov 13;342(8881):1209-10
7901532
Oncogene. 2001 Jul 12;20(31):4188-97
11464285
J Nutr. 2006 Jan;136(1):75-82
16365062
J Cell Biochem. 1998 Apr 1;69(1):44-54
9513045
Clin Cancer Res. 2002 Jul;8(7):2369-77
12114442
Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72
15134504
Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1055-65
9829717
Carcinogenesis. 2004 Sep;25(9):1649-57
15131010